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 1 
Abstract 1 
Background Equine surgery is commonly performed on standing sedated horses.  2 
Objectives To assess sedation, antinociception and gastrointestinal motility (GIM) after 3 
a detomidine loading dose followed by 2 hours constant rate intravenous (i.v.) infusion, 4 
with or without methadone in standing horses.  5 
Study design Seven healthy adult cross-bred horses, three geldings and four females, 6 
(404 ± 22 kg) participated in this blinded, randomized, crossover experiment.  7 
Methods Five i.v. treatments were administered: saline (SAL), detomidine low (2.5 8 
µg/kg bwt + 6.25 µg/kg bwt/h) (DL) and high (5 µg/kg bwt + 12.5 µg/kg bwt/h) (DH) 9 
alone or both combined with methadone (0.2 mg/kg bwt + 0.05 mg/kg bwt/h), (DLM) 10 
and (DHM), respectively. Head height above ground (HHAG), electrical (ET), thermal 11 
(TT) and mechanical (MT) nociceptive thresholds and GIM were evaluated at 12 
predetermined times between 5 and 240 minutes. Mixed effect model and Kruskal-Wallis 13 
(p < 0.05) were used for normal and non-normal data, respectively. 14 
Results Sedation (<50% of basal HHAG) was achieved only for the duration of the 15 
infusion and for a further 15 minutes in DH and DHM. Nociceptive thresholds were 16 
increased above baseline, to the greatest degree and for the longest duration with DHM 17 
(ET and TT for 135 minutes and MT for 150 minutes). After DH, TT was significantly 18 
higher than baseline from 30 to 120 minutes and MT from 15 to 135 minutes. After DLH, 19 
ET was increased at 90 minutes, TT at 30 minutes and MT for 120 minutes. Intestinal 20 
motility was reduced for up to 135 minutes after DL, 150 minutes after DLM and 210 21 
minutes after DH and DHM. 22 
Main limitations Nociceptive thresholds are not real surgical stimuli. 23 
Conclusion Treatment DHM produced sedation, with the most intense and consistent 24 
antinociception, with reduced GIM. Treatments DH and DLM provided comparable 25 
antinociception. 26 
 27 
 28 
 2 
Introduction 29 
In equine practice, surgery is often performed on standing, sedated horses, as general 30 
anaesthesia is still associated with a high mortality rate [1]. For example, procedures such 31 
as laparoscopy, dentistry, sinus trepanation and enucleation can be performed with the 32 
aid of intravenous (i.v.) sedative and analgesic constant rate infusion (CRI) combined 33 
with local anaesthesia [2,3]. Intravenous CRI aims to maintain steady plasma drug 34 
concentrations, leading to consistent sedation and analgesia. Infusions of α2-agonists 35 
alone [4-7] or in combination with opioids [5,6,7,8] are commonly used for this purpose.  36 
Detomidine CRI has been used under clinical conditions after loading doses of 15 37 
[9], 10 [10,11] and 7.5 [12] µg/kg bwt in prospective studies, and of 7.5 ± 1.87 µg/kg bwt 38 
(mean ± s.d.) in a retrospective study with 51 horses [13]. These reports describe a variety 39 
of protocols with mean infusion rates varying from 6.6 to 36 µg/kg bwt/h, with surgery 40 
duration of up to 170 minutes. An in-depth literature review revealed no publications 41 
evaluating the effects of simultaneous CRIs of detomidine and an opioid such as 42 
methadone in standing horses. 43 
 Identification of a protocol that provides analgesia and an appropriate degree of 44 
sedation for standing horses is challenging. Although most of the reported protocols 45 
appear to be based on personal clinical experience, recent refinements in sequential 46 
pharmacokinetic/pharmacodynamic (PK/PD) modelling allow concentration-effect data 47 
to be determined and the effects on different PD variables [i.e. height of head above the 48 
ground (HHAG), responses to nociceptive stimuli, intestinal motility] to be predicted 49 
according to plasma concentrations [14,15]. Based on data from previous studies using a 50 
number of bolus combinations of detomidine and methadone [16], PK/PD modelling [15] 51 
was used to simulate the effects of different doses and rates of detomidine and methadone 52 
on sedation, antinociception and gastrointestinal motility .    53 
Leading on from this, we aimed to identify a protocol under experimental 54 
conditions that provides antinociception without excessive sedation. Loading doses of 55 
detomidine at 2.5 and 5 µg/kg bwt combined with 0.2 mg/kg bwt methadone followed by 56 
infusion of detomidine (6.25 or 12.5 µg/kg bwt/h) and methadone (0.05 mg/kg bwt/h) 57 
were chosen according to the results of simulation [15,16]. Our hypothesis was that the 58 
higher doses and infusion rates of detomidine, when combined with methadone would 59 
produce antinociception with adequate.  60 
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 61 
Materials and methods 62 
The study was designed as a randomised, placebo‐controlled, observer‐blinded, crossover 63 
experiment. Each horse received all treatments with a 1‐week washout period between 64 
treatments. The study was performed during March and April of 2017, at the farm 65 
facilities of the School of Veterinary Medicine and Animal Science, São Paulo State 66 
University (UNESP), Botucatu (Brazil) where all the horses were born and lived. Each 67 
horse was always treated at the same time of day. 68 
 69 
Animals 70 
Seven docile, healthy adult cross‐bred horses (three geldings, four mares), 9–11 71 
years and weighing 372–450 kg were enrolled in the study. All had been trained using 72 
positive reinforcement and used in similar antinociceptive studies. The horses were kept 73 
at pasture and brought in to covered pens with outdoor access for at least 12 h, with water 74 
ad libitum, commercial feed and hay provided until each experiment began. The animals 75 
were classified as healthy ASA I (American Society of Anesthesiologists) according to 76 
physical, musculoskeletal and lameness examination, haematology and biochemistry 77 
(complete haemogram, blood urea nitrogen, aspartate and alanine transaminases, gamma 78 
glutamyl transferase and alkaline phosphatase), performed 1–2 weeks before beginning 79 
the study. No drugs such as sedatives, analgesics, corticosteroids or nonsteroidal anti‐80 
inflammatory drugs were administered by any route for at least 1 month prior to the study. 81 
The sample size was estimated based on the sedative (HHAG) and antinociceptive 82 
results of a pilot study [α = 0.05, β = 0.80, 5 treatments and the differences between means 83 
and expected general s.d., (https://www.statstodo.com/SSizUnpairedDiff_Pgm.php)], 84 
and on previous data from studies in the same group of horses with similar methodology 85 
[16-18]. 86 
 87 
Study design 88 
On the day of the experiment, each animal was weighed and fly repellent was applied to 89 
the skin. The hair over both jugular veins was clipped for catheter placement and the skin 90 
disinfected. Thereafter, 1 ml of 2% lidocaine (Cristália Produtos Químicos Farmacêuticos 91 
Ltda, São Paulo, Brazil) was injected subcutaneously and one 14-gauge catheter (G14 x 92 
70 mm (Delta Med SRL, Viadan, Italy) was placed for drug administration. 93 
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The hair over the middle third of the dorsal aspect of both metacarpals was clipped 94 
for placement of the thermal probe (right) and mechanical actuator (left). The hair 95 
immediately proximal to the coronary band of the left thoracic limb was clipped for 96 
placement of the electrical electrodes. A strict clipping and cleaning protocol was 97 
followed in order to ensure good contact and to minimize between-electrode resistance to 98 
below 3 kiloohms (kΩ) [16,19]. 99 
Each horse was then led to the experimental room (6 m2, without windows), 100 
previously sprayed with fly repellent. Thirty minutes were allowed for familiarization. 101 
During this period, two adhesive electrodes (2223BRQ; 3M do Brasil Ltda, São Paulo, 102 
Brazil) were placed on the prepared area at the left coronary band, separated by 8 cm and 103 
secured with adhesive strips around the hoof. A commercial horse-blanket (Topcat 104 
Metrology Ltd, Ely, UK) was placed on the horse’s back and the thermal (WTT2; Topcat 105 
Metrology Ltd, Ely, UK) and mechanical (WTT1 - Topcat Metrology Ltd, Ely, UK) 106 
control units, remotely controlled with infrared signals, were attached with Velcro. The 107 
thermal probe and mechanical actuator were attached to the limbs and connected to the 108 
control units after the horse was placed in the restraining stocks. A blood pressure cuff 109 
(DURA‐CUF CRITIKON 17–25 cm; GE Healthcare, Helsinki, Finland) was placed at 110 
the base of the tail to measure heart rate (HR) and systolic arterial blood pressure (SAP) 111 
using a non invasive Doppler system (Model 812 - Parks Medical Electronics, Inc., Aloha, 112 
Oregon, USA). 113 
The five treatments were all comprised of a bolus injection followed by a 2 hour 114 
CRI, assigned using a randomization website (https://sorteador.com.br). The treatments 115 
were: saline (SAL) (Fresenius Kabi, São Paulo, Brazil), detomidine low dose (DL) (2.5 116 
µg/kg bwt detomidine; Ourofino Saúde Animal, São Paulo, Brazil; followed by a CRI of 117 
6.25 µg/kg bwt/h), detomidine high dose (DH) (5 µg/kg bwt detomidine; followed by a 118 
CRI of 12.5 µg/kg bwt/h), detomidine low dose with methadone (DLM) (2.5 µg/kg bwt 119 
detomidine + 0.2 mg/kg bwt methadone; Cristália Produtos Químicos e Farmacêuticos 120 
Ltda, São Paulo, Brazil; followed by 2 CRIs, detomidine 6.25 µg/kg bwt/h + methadone 121 
0.05 mg/kg bwt/h), and detomidine high dose with methadone (DHM) (5 µg/kg bwt 122 
detomidine + 0.2 mg/kg bwt methadone; followed by 2 CRIs, detomidine 12.5 µg/kg 123 
bwt/h + methadone 0.05 mg/kg bwt/h). All bolus doses and infusions were diluted by an 124 
assistant investigator (M.W.F.) with saline to 10 and 18 ml, respectively, in order to keep 125 
the main investigator blinded. The CRIs were delivered by two calibrated syringe drivers 126 
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(DigiPump SR8x;Digicare Biomedical Technology Inc, Boynton Beach, Florida, USA; 127 
and Pilot Anestesia; Fresenius Vial, Brezins, France). 128 
Sedation and responses to noxious stimuli were evaluated in triplicate for baseline 129 
values before drug administration (T0), and once only at T5 (5 minutes after drug 130 
administration), T15, T30, T60, T90, T120, T135, T150, T180, T210 and T240. Intestinal 131 
motility was scored at the same time points starting at T15. Evaluation of the variables is 132 
described elsewhere [16] and summarised briefly below: 133 
 134 
Sedation  135 
The sedation variables were always evaluated by a single investigator (A.R.O.) who was 136 
unaware of the treatment identity. To evaluate the degree of sedation, the height above 137 
the ground of the lower lip (HHAG) was measured against a scale on the wall [5,6]. 138 
Quality of sedation was scored using numerical rating scales (NRS) evaluating the degree 139 
of ataxia as well as responses to tactile, acoustic and visual stimuli, always in this order. 140 
Ataxia and response to stimulus were scored from 0 to 3 (0 no ataxia, no response; 3 141 
maximal ataxia, maximal response) (Appendix A).   142 
 143 
Nociceptive threshold testing 144 
Nociceptive stimuli were applied at each time point immediately after the sedation 145 
scoring, and the response were all evaluated by the main investigator (M.G.M), also 146 
blinded to the treatment identity. Stimuli were always applied in the same order: 147 
electrical, thermal, mechanical. Aversive reactions were considered positive responses 148 
when the horse lifted its foot, pawed the ground, stamped, flexed the limb or walked to 149 
avoid the stimulus [20].  150 
 151 
Electrical threshold testing 152 
Before each electrical stimulus was applied, a digital multimeter (XX) was used to 153 
confirm that the resistance between electrodes was < 3 kΩ [19]. The stimulus consisted 154 
of a pulsatile current of 10 millisecond square waves (ms) at 10 Hertz (Hz), delivered by 155 
an electrical stimulator. The voltage, initiated at 1 Volt (V), was increased in steps of 1 V 156 
every 5 seconds and was stopped immediately after an avoidance response was seen or 157 
the voltage reached 20 V.  158 
 159 
Thermal threshold testing 160 
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A thermal probe with a heating element (probe 3) [21], connected to the thermal control 161 
unit, was placed on the clipped area of the dorsal aspect of the right metacarpus and 162 
attached with an elasticated band secured by Velcro. The skin temperature was recorded 163 
in degrees Celsius (°C) after at least 5 minutes equilibration. The ramped stimulus 164 
(heating at 0.8 °C/s) was then applied via the automatic wireless control system until a 165 
positive response was observed or the cut-out at 60 °C reached. In order to avoid focal 166 
tissue damage, the probe was moved 1-2 cm proximally on the limb after each stimulus, 167 
independent of the temperature reached [16]. 168 
 169 
Mechanical threshold testing 170 
A pneumatic actuator with a 1 mm round-ended pin [22] was held with a brushing boot 171 
on the clipped area of the dorsal aspect of the left metacarpal area (mid bone), tensioned 172 
against the leg with an elasticated band secured with Velcro and connected to the control 173 
unit with non-distensible tubing. The force in Newtons (N) of the pin pressing on the skin 174 
surface was increased at 0.8 N/s by the automatic wireless control system. The stimulus 175 
was stopped when an aversive response was observed or the cut-out value of 20 N 176 
reached. 177 
 178 
Cardiopulmonary variables 179 
Each SAP value was corrected according to the height difference between the shoulder 180 
joint and the cuff, taking the shoulder joint to represent the level of the right atrium of the 181 
heart. A height difference of 10.2 cm was considered to be equivalent to 7.5 mmHg. The 182 
respiratory rate (RR) was measured by observation of chest movements over 15 seconds. 183 
 184 
Abdominal auscultation 185 
The main investigator (M.G.M) auscultated each of the four abdominal quadrants (right 186 
dorsal, right ventral, left dorsal and left ventral) for 1 minute each and awarded a motility 187 
score, from 0 to 5 according to Boscan et al. (2006) [23]. The sum of the scores was 188 
recorded, ranging from 0 to 20 (0 no motility, 20 maximal motility possible).   189 
 190 
 191 
Statistical Analysis  192 
For each variable, normality was assessed graphically and with normality tests (Shapiro-193 
Wilk). Descriptive measurements were generated. For parametric variables, the mixed 194 
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model ANOVA with Tukey’s post-hoc test was used to evaluate the differences between 195 
treatments and time points; data are shown as mean ± s.d. For non-parametric variables, 196 
Friedman’s test with Dunn’s post-hoc test was used; data are shown as median (range). 197 
A significance level less than 0.05 was adopted for all analysis and the calculations were 198 
made with the aid of Statistical Analysis Software - SAS version 9.4. 199 
 200 
Results  201 
All the horses received all treatments and completed the study without complications. 202 
They ate and defecated normally at the end of each session, without signs of abdominal 203 
discomfort.  204 
 205 
Sedation 206 
Sufficient sedation (< 50% of basal HHAG) [6] was only achieved for the duration of the 207 
infusion and for 15 minutes more in DH and DHM. Significant differences within and 208 
between treatments are shown in Figure 1. 209 
  210 
Ataxia scores were significantly higher than baseline [0 (0 – 0)] after DHM at T30 211 
[2 (1 – 3)] and T60 [2.5 (1 – 3)]. Comparing treatments, ataxia was more pronounced 212 
after DHM than SAL at T15 [2 (1 – 3)] versus [0 (0 – 1)], and at T30 [2 (1 – 3)], T60 [2.5 213 
(1.5 – 3)], T90 [1.5 (1 – 3)] and T120 [2 (1 – 3)] versus [0 (0 – 0)], and than DL at T15 214 
[2 (1 – 3)] versus [0 (0 – 1)]. Scores for responses to tactile stimuli were lower at T5 than 215 
SAL [3 (2 – 3)] after DHM [1 (0 – 3)], at T30 [3 (2 – 3)] versus [0.5 (0 – 2)], at T60 [3 (2 216 
– 3)] versus [1 (0 – 3)] and at T90 [3 (1 – 3)] versus [1.5 (0 – 3)]. Scores for responses to 217 
tactile stimuli were lower than baseline [2 (1 – 3)] only for treatment DL at T30 and at 218 
T60 [0.5 (0 – 1)]. Between treatments, scores were lower at T60 after DL [0.5 (0 – 1)] 219 
than SAL [2 (1 – 2)].  220 
 221 
Nociceptive threshold testing 222 
Treatment DHM resulted in the highest thresholds for all the 3 stimuli as well as being 223 
responsible for most of the cut-out values reached for the thermal and mechanical 224 
modalities: nociceptive thresholds increased above baseline, to the greatest degree and 225 
for the longest duration (electrical and thermal for 135 minutes and mechanical for 150 226 
minutes). Treatments DH and DLM provided comparable antinociception. Significant 227 
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differences within and between treatments are shown in Figures 2, 3 and 4 for electrical, 228 
thermal and mechanical thresholds, respectively. 229 
 230 
Abdominal auscultation 231 
Intestinal motility was reduced for up to 135 minutes after DL, 150 minutes after DLM 232 
and 210 minutes after DH and DHM. Significant differences within and between 233 
treatments are shown in Figure 5. 234 
  235 
 Throughout the study period, cardiovascular function was maintained well within 236 
acceptable limits in all horses undergoing all treatments, with no differences from 237 
baseline and between treatments for HR, and only one single difference at one time point 238 
from baseline for SAP (Table 2). All treatments produced a reduction in the RR that 239 
persisted for 60 and 90 minutes following the end of infusion of detomidine low and high 240 
doses, respectively. 241 
One horse overreacted with mild ‘head shaking’ to acoustic and visual stimuli for 242 
up to T30 when receiving treatment DLM. No other complications were observed.  243 
  244 
Discussion 245 
This study indicates that the higher detomidine dose combined with methadone (treatment 246 
DHM) produced the most intense and consistent antinociception of all the protocols for 247 
the three stimuli. Sedation and effects on intestinal motility were similar to the high dose 248 
of detomidine alone. Low doses of detomidine with or without methadone produced less 249 
antinociception and sedation but still reduced intestinal motility for the duration of the 250 
infusion, although normal scores returned faster. 251 
 According to our results, treatment DHM produced the most intense 252 
antinociceptive effects and these were maintained during the whole 2-hours infusion 253 
period. The low dose of detomidine did not produce any antinociception, however when 254 
methadone was included, antinociception was mild and similar to that observed with the 255 
high dose of detomidine alone, showing that methadone enhanced the detomidine-256 
induced antinociception in a similar manner to that with detomidine boli of 5 [16] and 10 257 
µg/kg bwt [17,18].  258 
 Sedation indicated by more than or equal to a 50 % reduction in HHAG was 259 
similar to that observed after a bolus of 5 µg/kg bwt of detomidine as reported previously 260 
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[16], and described as ‘sufficient’ sedation [6]. According to this criteria, overall, only 261 
horses treated with the high dose of detomidine were ‘sufficiently’ sedated. In contrast, 262 
low doses of detomidine, regardless of the inclusion of methadone, produced less 263 
sedation. This is important if these protocols are used in horses undergoing standing 264 
surgery when an adequate degree of sedation is essential. With regard to the quality of 265 
sedation, some degree of ataxia and reduction in the responses to stimuli are inevitable 266 
when a high dose and infusion rate of detomidine are used in combination with 267 
methadone. 268 
Cardiovascular function remained within clinically acceptable limits. The low 269 
dose of detomidine kept the cardiovascular effects of this drug to a minimum [16]. A 270 
reduction in the RR was noted in all treated horses to a similar degree, and lasted 271 
throughout the two hours infusion, with slight improvement towards the end of the 272 
experiment. Reductions in RR occurred when the drugs were administered as single boli, 273 
alone or in combination [16]. 274 
 All treatments reduced intestinal motility; the higher doses of detomidine 275 
produced the greatest effects and for the longest period after the end of the infusion. 276 
Similar results were also observed when these drugs were given as boli [16], as well as 277 
by simulation based on PK/PD models [15]. Although no signs of colic were observed, 278 
the reduction in the motility scores suggests that horses would benefit from a close follow-279 
up after clinical treatment during the first 12 – 24 hours.  280 
Taking into account the above considerations, the combination of methadone and 281 
the highest dose of detomidine appears to be the most promising treatment for more 282 
invasive surgical procedures. Detomidine at 5 µg/kg bwt with 0.2 mg/kg bwt of 283 
methadone also provided antinociception with adequate sedation in a previous report [16]. 284 
For prolonged maintenance of sedation and antinociception, the 12.5 µg/kg bwt/h rate for 285 
detomidine co-administered with methadone appeared to be the best of all the treatments 286 
studied here. When given alone, detomidine infusion rates of around 9 µg/kg bwt/h were 287 
successfully used for laparoscopy [9,10], whereas rates of approximately 20 µg/kg bwt/h 288 
were required for dental or sinus procedures [11,12]. More clinical studies are needed to 289 
determine if the DHM protocol might be useful, or if the rate should be adapted to 290 
different surgical procedures.  291 
We used the synthetic opioid methadone in order to enhance the sedative 292 
properties of detomidine, to provide analgesia [24], and to reduce the doses and infusion 293 
rates of the α2-agonist. To date, the use of methadone as a co-infusion with an α2-agonist 294 
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has not been reported in horses. Excitatory effects, such as head shaking, linked to the 295 
use of 0.2 mg/kg bwt of methadone [17] may be present, especially when using low doses 296 
of detomidine. In the present study, only one horse showed mild ‘head The κ- agonist 297 
butorphanol is the opioid that has been the most widely studied for use in a CRI [5-8], but 298 
methadone, as a full µ-agonist, might be more appropriate in more painful surgeries. Two 299 
reports suggest that buprenorphine, a partial µ-agonist opioid, when combined with 300 
detomidine infusion, although contributing to antinociception, may lead to abdominal 301 
pain and increase locomotor activity [11,12]. However, minimal complications were 302 
observed in a large clinical study in horses sedated with romifidine and buprenorphine 303 
[25]. 304 
 Most of the protocols used for standing sedation in horses are based on clinical 305 
experience, experimental [4-10], clinical [11,12] or retrospective [13] studies. Our study 306 
is innovative in equine research as we used the data from our previous boli study [16], to 307 
perform PK/PD modelling [15] and set dose/rates ranges that would allow different 308 
degrees of sedation and antinociception for this experimental study. Therefore, modelling 309 
will allow us to predict more precisely the expected effects of future clinical trials.   310 
The main limitation of our study is the extrapolation of the results to a clinical 311 
scenario as: (i) nociceptive thresholds are not real surgical stimuli, even when validated 312 
for experimental studies in standing horses [20]; (ii) surgical pain in different locations 313 
may differ in intensity due to specific innervation; and (iii) understanding of the 314 
magnitude of inter-animal variability is limited from a group of 7 horses. Study of a larger 315 
clinical population undergoing a range of standing surgical procedures is needed to 316 
confirm the predicted clinical effects. 317 
 318 
Conclusions 319 
In conclusion, the treatment with the highest dose of detomidine combined with 320 
methadone produced the most intense and consistent antinociception, with minimal 321 
adverse effects. This protocol might be useful for clinical surgical procedures. Future 322 
studies are justified to evaluate its clinical applicability in standing horses. 323 
 324 
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